NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 85.95.
| Share Price | ₹16,125.0 | Dec 16,2025 |
| Market Cap | ₹20,640.0 Cr | |
| Earnings-TTM | ₹240.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 85.95x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹20,640.0 Cr] as on Dec 16,2025
(/) Earnings [ ₹240.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 85.95x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 85.95 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 30.88x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NEULAND LABORATORIES | 240.15 | 85.95 | 20,640.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.67 | 427,753.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 67.69 | 168,205.0 |
| CIPLA LTD | 5,453.86 | 22.22 | 121,166.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 59.42 | 127,169.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.66 | 106,749.0 |
| MANKIND PHARMA LTD | 1,767.06 | 49.21 | 86,953.3 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.49 | 91,959.7 |
| LUPIN LTD | 4,347.53 | 21.96 | 95,455.0 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.85 | 68,430.0 |
| ABBOTT INDIA LTD | 1,508.95 | 39.18 | 59,122.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.49x |
| Max industry PE | 85.95x |
| Median industry PE | 39.18x |
| Average industry PE | 40.30x |
You may also like the below Video Courses